VGXI
Address: 2700 Research Forest Drive Suite 180, The Woodlands, Texas. Tx 77381About Us
VGXI is a contract manufacturing organization that produces DNA plasmids under GMP for human clinical trials. With nearly 20 years experience manufacturing biopharmaceuticals, VGXI has produced over 175 batches of clinical grade DNA for trials in the U.S., Canada, Europe, Asia, and Australia. The Company’s patented AIRMIX® lysis technology enables high purity, highly concentrated plasmid formulations from 1 to 15 mg/ml allowing customers to prepare low volume and multi-plasmid formulations. Its world-class process development scientists and purpose-built GMP production facility combine to ensure the success of challenging clinical programs.
Sectors
- Contract Research & Development
- Contract Manufacturing
Categories
- Biologics
- Biotechnology
- BioPharmaceuticals
- Plasmid DNA
- Cell Banking
- Fermentation
- Clinical Trial Manufacturing
- Gene Therapy
- Nucleic Acids
- Bioprocess Development
- Immunotherapy
- Vaccine Products
News
VGXI Inc. announces a strategic partnership with Sutro Biopharma Inc. to support growing clinical pipeline
CONROE, Texas, June 3, 2024 /PRNewswire/ -- VGXI, Inc., a leading contract developer and manufacturer (CDMO) specializing in nucleic acid biopharmaceuticals, including gene therapies, DNA vaccines, and RNA medicines, has entered into a strategic partnership with Sutro Biopharma, Inc. (Sutro) to support clinical production of luveltamab tazevibulin, abbreviated as "luvelta", a novel Folate Receptor-α (FRα)-targeting antibody-drug conjugate (ADC) with the potential to address the unmet need in several FRα-expressing cancers.
Source: The Partnership Tree | https://www.pharmaservicesdirectory.com